The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The increasing prevalence of hypertension disorders is expected to drive the growth of the ACE inhibitors market going forward.

• High Blood Pressure Epidemic:
  • Over the last 30 years, there has been a significant increase in hypertension cases globally, with approximately 1.28 billion adults affected by hypertension.
  • Around 46% of adults with hypertension remain undiagnosed, contributing to the severity of the condition.
• Market Dynamics:
  • ACE inhibitors are crucial medications in managing hypertension, aiding in relaxing blood vessels and reducing blood pressure.
  • Major players in the market include Pfizer Inc., Novartis AG, Johnson & Johnson, and others.

Product Innovations Drive Growth In ACE Inhibitors Market
Product innovations are a key trend gaining popularity in the ACE inhibitors market.

• Strategic Focus:
  • Companies are emphasizing the development of innovative products to enhance their market presence.
  • For instance, Travere Therapeutics received FDA approval for FILSPARI, a non-immunosuppressive therapy for IgA nephropathy.
• Treatment Advancements:
  • Innovations include systemic glucocorticoids, ACE inhibitors, and antihypertensive medications to address various conditions like chronic kidney disease and hypertension.

Read More On The ACE Inhibitors Market Report 2024 – https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Astrazeneca Bolsters Cardiorenal Pipeline With Acquisition Of CinCor Pharma
In January 2023, AstraZeneca’s acquisition of CinCor Pharma for $1.3 billion is set to enhance its cardiorenal pipeline.

• Strategic Acquisition:
  • The move aims to expand AstraZeneca’s product line of aldosterone synthase inhibitors (ASI) for blood pressure lowering in treatment-resistant hypertension.
• CinCor Pharma’s Focus:
  • CinCor Pharma, a US-based biopharmaceutical company, focuses on developing novel treatments for resistant hypertension and chronic kidney disease.

Market Segmentation and Regional Insights
The ACE inhibitors market is segmented across various parameters, including type, drug, dosage form, application, and end-users.

• Segmentation Details:
  • Types of ACE inhibitors include Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, and Phosphonate-containing Agents.
  • Popular drugs in this category include Ramipril, Enalapril, Benazepril, and others.
  • Applications span Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, and more.
  • End-users range from Hospitals to Online Drug Stores.
• Regional Analysis:
  • North America held the largest share in 2023, while Asia-Pacific is anticipated to witness the fastest growth during the forecast period.

Conclusion
The ACE inhibitors market is poised for substantial growth, fueled by rising hypertension rates and product innovations. Strategic acquisitions and market segmentation play pivotal roles in shaping the industry landscape. As healthcare needs evolve and awareness increases, the market is expected to witness dynamic transformations, presenting opportunities for both established players and emerging entrants. With a focus on patient-centric approaches and regulatory compliance, the ACE inhibitors market is set to address the burgeoning global burden of cardiovascular diseases effectively.

Request for A Sample Of The Global ACE Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=10671&type=smp